We aimed at evaluating the efficacy and durability of a lopinavir/ritonavir-based dual regimen (LPV/r-DR) in virologically controlled HIV-infected individuals in current clinical practice. Methods: Patients who have initiated for the first time a LPV/r-DR with HIV-RNAB50 copies/mL were included in this observational study. The main endpoints were: time to virological rebound [VR 0time of first of two consecutive viral loads (VL)50 copies/mL] and time to experience either a single VL200 copies/mL or discontinuation/intensification ( 0 treatment failure, TF). Individuals' follow-up accrued from the date of starting the LPV/r-DR to event or last available VL. Kaplan-Meier curves and Cox regression analysis were used. Covariates included in the multivariable analysis were gender, age, route of transmission, hepatitis co-infection, calendar year of starting the DR, nadir CD4' count, VL at initiation of first cART, previous failures to protease inhibitors (PIs), time with undetectable VL before starting the DR and the type of DR [nucleoside reverse transcriptase (NRTI), non-NRTI (NNRTI), raltegravir or maraviroc, with NRTI as reference group]. Results are presented as median (Q1, Q3) or frequency (%) as appropriate. Results: 108 individuals followed for 18 (7, 30) months were included; baseline (BL) characteristics are detailed in Table 1 . LPV/r was associated with a NRTI in 51, with a NNRTI in 10, with raltegravir in 29, and with maraviroc in 18 individuals. By 36 months from switching to the LPV/r-DR, the proportion of individuals with VR and TF was 10% (95% CI 3Á17%) and 36% (95% CI 22Á50%), respectively. We did not find any factor independently associated with the risk of VR. Older age (ARH 00.49 (95% CI 0.30Á0.78) per 10 years older; p 00.003) was found to be protective from TF. Mean (SE) CD4' cells/mL increase from BL to month 36 resulted significant: 195 (40.1) cells/mL (p00.0028). We did not observe significant changes in AST, ALT, eGFR (MDRD formula), triglycerides and both total and HDL-cholesterol. Conclusions: A LPV/r-DR can be considered a valuable option in patients with HIV-RNAB50 copies/mL and ongoing toxicity from the third drug of the regimen, although up to 17% of patients showed viral rebound by 3 years. Older patients are at lower risk of failure with this strategy, but larger sample size is needed to identify who might benefit from this strategy instead of others.

